Working… Menu

Ablation Versus Medical Management of Atrial Fibrillation in HFpEF (AMPERE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04282850
Recruitment Status : Recruiting
First Posted : February 25, 2020
Last Update Posted : April 9, 2021
Biosense Webster, Inc.
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction (HFpEF).

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Heart Failure With Normal Ejection Fraction Procedure: Pulmonary Vein Isolation Not Applicable

Detailed Description:

Recent studies using PVI for rhythm control in patients with heart failure with reduced ejection fraction (HFrEF) have shown improvement in systolic ejection fraction, exercise capacity, quality of life, and a significant reduction in all-cause mortality. The PVI procedure has been shown to be safe and comparably effective in treating Atrial Fibrillation (AF) in HFpEF patients, but no studies have yet demonstrated the effects of catheter ablation on exercise capacity or clinical outcomes.

The investigators propose a prospective, non-blinded randomized control pilot study to assess the feasibility of conducting larger scale studies to determine if there are differences between catheter ablation with medical management on exercise capacity and quality of life in HFpEF patients with AF. The investigators' study will be powered for AF burden reduction, and the investigators hope to use the effect size on exercise capacity and heart failure events to help determine power for larger clinical studies that will follow to shed light on how invasive management of atrial fibrillation may impact the natural history of individuals with these two cardiovascular conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 2:1 randomization to catheter ablation (PVI) or to medical management.
Masking: Single (Outcomes Assessor)
Masking Description: Serum biomarkers, atrial fibrillation burden, anatomical and functional echocardiographic parameters, and exercise capacity will all be measured and analyzed by study personnel blinded to the patient's intervention.
Primary Purpose: Treatment
Official Title: Ablation Versus Medical Management of Atrial Fibrillation in Heart Failure With Preserved Ejection fRaction and the Effects on Exercise Capacity (AMPERE)
Actual Study Start Date : February 29, 2020
Estimated Primary Completion Date : January 2025
Estimated Study Completion Date : January 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Pulmonary Vein Isolation (PVI) Group
Subjects randomized to this treatment arm will undergo atrial fibrillation ablation, and undergo routine post-procedural follow-up.
Procedure: Pulmonary Vein Isolation
The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
Other Name: Atrial fibrillation ablation

No Intervention: Medical Management
Subjects randomized to this treatment arm will undergo medical management of the arrhythmia, but will not undergo invasive electrophysiologic procedures to address subject's AF.

Primary Outcome Measures :
  1. Change in AF burden as assessed by difference in percentage of time an individual is in AF [ Time Frame: 3, 6, 9, and 12 months from intervention ]
    AF burden, described as the percentage of time an individual is in AF relative to the total amount of time analyzed. This outcome will be assessed at multiple intervals following intervention arm, using a continuous, implantable heart rhythm monitor. The investigators' focus will be on the change between pre-intervention AF burden and AF burden at 6 month follow-up.

Secondary Outcome Measures :
  1. All-cause mortality [ Time Frame: 12 months ]
    All deaths within 12 months of the intervention arm.

  2. Number of cardiovascular mortalities [ Time Frame: 12 months ]
    The number of deaths attributable to cardiovascular causes occurring within 12 months of the intervention arm

  3. Number of all-cause hospitalizations [ Time Frame: 12 months ]
    The total number of inpatient hospitalizations within 12 months following the intervention.

  4. Number of heart failure hospitalizations [ Time Frame: 12 months ]
    The total number of inpatient hospitalizations attributable to heart failure exacerbations within 12 months following the intervention.

  5. Change in patient-reported quality of life as assessed by Kansas City Cardiomyopathy Questionnaire [ Time Frame: At enrollment (baseline) and 6 months following intervention ]
    The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. A change of 10 points or more is considered not only clinically significant but also carries prognostic implications for event-free survival in heart failure patients.

  6. Change in NT pro-BNP levels [ Time Frame: At enrollment (baseline) and 6 months following intervention ]
    Serum biomarker associated with congestive heart failure symptoms, measured in (mg/ml).

  7. Change in exercise capacity as assessed by the 6 minute walk distance test [ Time Frame: At baseline and 6 months post intervention ]
    Pre-intervention arm and 6 month post-procedural exercise capacity will be assessed using change in 6 minute walk distance, defined as the total distance (in meters) traversed during 6 minutes of time. This is well-validated measure of functional capacity and prognostic marker in patients with heart failure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • between 18 to 90 years of age, male or female
  • Left Ventricular Ejection Fraction (LVEF) > 50% by echocardiogram during routine screening or within 12 months prior to enrollment day.
  • Symptoms of heart failure requiring treatment with diuretic therapy for at least 30 days preceding enrollment.
  • Symptomatic paroxysmal or persistent atrial fibrillation.
  • Paroxysmal atrial fibrillation defined as recurrent AF (at least 2 episodes) that terminated spontaneously within 7 days
  • Persistent AF was defined as AF which is sustained beyond 7 days, or lasting less than 7 days but necessitating pharmacologic or electrical cardioversion
  • Included within the category of persistent AF is "long-standing persistent AF" defined as continuous AF of greater than 1 year in duration
  • AF episodes had to be documented in the last 3 months prior to enrollment by ECG, Holter monitor, Loop recorder, memory of the implanted device, or any suitable device.
  • Current symptoms of heart failure (NYHA II-IV) at the enrollment visit (Visit 1)
  • Structural heart disease evidenced by one or both of the following echocardiographic findings (done during the transthoracic echocardiography (TTE) within 6 months of enrollment)
  • Left atrial enlargement (LAE) defined as LA width > 3.8 cm or LA length > 5.0 cm, or LA area > 20 cm2 or LA volume > 55 mL or LA volume index > 29 ml/m2. (of note, LA length greater than 6.0 cm will be excluded)
  • Left ventricular hypertrophy (LVH) defined by septal thickness or posterior wall thickness > 1.0 cm
  • And at least one of the following:
  • A heart failure hospitalization lasting over 12 hours and including intravenous diuretics at a healthcare facility within 12 months prior to the enrollment visit.
  • An elevated pro-brain natriuretic peptide (BNP) (>100 pg/mL, or N-terminal pro b-type natriuretic peptide (NT-proBNP)>300 pg/mL)
  • Hemodynamic testing consistent with HFpEF physiology including pulmonary capillary wedge pressure (PCWP) (or LVEDP) ≥ 15 mmHg.

Exclusion Criteria:

  • Previous left heart ablation procedure for AF
  • Contraindication to chronic anticoagulation therapy or heparin
  • Longstanding atrial fibrillation, defined here as greater than 3 years of persistent atrial fibrillation
  • Severe left atrial dilatation, with LA length > 6.0 cm, optimally from parasternal long view
  • Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG) ST segment depression or prominent T-wave inversion and/or positive biomarkers of necrosis (e.g. troponin) in the absence of ST-segment elevation and in an appropriate clinical setting (chest discomfort or angina equivalent).
  • Cardiac surgery, angioplasty, or cerebrovascular accident within 4 weeks prior to enrollment.
  • Planned cardiovascular intervention
  • Listed for heart transplant
  • Cardiac assist device implanted or need for mechanical hemodynamic support or inpatient admission
  • Life expectancy less than 1 year
  • Uncontrolled hypertension, defined as resting systolic blood pressure >190 and/or resting diastolic pressure>110
  • Chronic Kidney Disease (CKD) stage 4-5 (GFR<25 ml/min/1.73m2), or on hemodialysis
  • Cardiac diagnosis in addition to or other than HFpEF:
  • Active myocarditis
  • Hypertrophic obstructive cardiomyopathy
  • Severe valvular disease
  • Restrictive or constrictive cardiomyopathy, including known amyloidosis, sarcoidosis, hemochromatosis
  • Complex congenital heart disease
  • Constrictive pericarditis
  • Severe pulmonary hypertension (RVSP > 60 mmHg), not secondary to HFpEF
  • Non-cardiac pulmonary edema
  • Clinical evidence of digoxin toxicity
  • Sepsis
  • Inability to comply with planned study procedures
  • Pregnancy or nursing mothers
  • Uncontrolled hypothyroidism or hyperthyroidism
  • BMI of >65 kg/m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04282850

Layout table for location contacts
Contact: Eunice Yang, MD 410-614-8449
Contact: Carol Tunin, PhD 410 502-1417

Layout table for location information
United States, Maryland
Johns Hopkins Hospital Recruiting
Baltimore, Maryland, United States, 21287
Contact: Eunice Yang, MD    410-614-8449   
Contact: David Spragg, MD   
Principal Investigator: David Spragg, MD         
Sub-Investigator: Eunice Yang, MD         
Sub-Investigator: Hugh Calkins, MD         
Sub-Investigator: Kavita Sharma, MD         
Sponsors and Collaborators
Johns Hopkins University
Biosense Webster, Inc.
Layout table for investigator information
Study Chair: Hugh Calkins, MD Johns Hopkins University
Principal Investigator: David Spragg, MD Johns Hopkins University
Study Director: Kavita Sharma, MD Johns Hopkins University
Layout table for additonal information
Responsible Party: Johns Hopkins University Identifier: NCT04282850    
Other Study ID Numbers: IRB00182159
First Posted: February 25, 2020    Key Record Dates
Last Update Posted: April 9, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Atrial Fibrillation
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes